Cargando…
Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disorder that is implicated in dysregulations in multiple biological pathways, orchestrated by interactions between genetic predisposition, metabolic syndromes and environmental factors. The limited knowledge of its pathogenes...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693407/ https://www.ncbi.nlm.nih.gov/pubmed/36355164 http://dx.doi.org/10.3390/metabo12111081 |
_version_ | 1784837533853548544 |
---|---|
author | Lin, Xiangping Liu, Xinyu Triba, Mohamed N. Bouchemal, Nadia Liu, Zhicheng Walker, Douglas I. Palama, Tony Le Moyec, Laurence Ziol, Marianne Helmy, Nada Vons, Corinne Xu, Guowang Prip-Buus, Carina Savarin, Philippe |
author_facet | Lin, Xiangping Liu, Xinyu Triba, Mohamed N. Bouchemal, Nadia Liu, Zhicheng Walker, Douglas I. Palama, Tony Le Moyec, Laurence Ziol, Marianne Helmy, Nada Vons, Corinne Xu, Guowang Prip-Buus, Carina Savarin, Philippe |
author_sort | Lin, Xiangping |
collection | PubMed |
description | Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disorder that is implicated in dysregulations in multiple biological pathways, orchestrated by interactions between genetic predisposition, metabolic syndromes and environmental factors. The limited knowledge of its pathogenesis is one of the bottlenecks in the development of prognostic and therapeutic options for MAFLD. Moreover, the extent to which metabolic pathways are altered due to ongoing hepatic steatosis, inflammation and fibrosis and subsequent liver damage remains unclear. To uncover potential MAFLD pathogenesis in humans, we employed an untargeted nuclear magnetic resonance (NMR) spectroscopy- and high-resolution mass spectrometry (HRMS)-based multiplatform approach combined with a computational multiblock omics framework to characterize the plasma metabolomes and lipidomes of obese patients without (n = 19) or with liver biopsy confirmed MAFLD (n = 63). Metabolite features associated with MAFLD were identified using a metabolome-wide association study pipeline that tested for the relationships between feature responses and MAFLD. A metabolic pathway enrichment analysis revealed 16 pathways associated with MAFLD and highlighted pathway changes, including amino acid metabolism, bile acid metabolism, carnitine shuttle, fatty acid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism and steroid metabolism. These results suggested that there were alterations in energy metabolism, specifically amino acid and lipid metabolism, and pointed to the pathways being implicated in alerted liver function, mitochondrial dysfunctions and immune system disorders, which have previously been linked to MAFLD in human and animal studies. Together, this study revealed specific metabolic alterations associated with MAFLD and supported the idea that MAFLD is fundamentally a metabolism-related disorder, thereby providing new perspectives for diagnostic and therapeutic strategies. |
format | Online Article Text |
id | pubmed-9693407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96934072022-11-26 Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach Lin, Xiangping Liu, Xinyu Triba, Mohamed N. Bouchemal, Nadia Liu, Zhicheng Walker, Douglas I. Palama, Tony Le Moyec, Laurence Ziol, Marianne Helmy, Nada Vons, Corinne Xu, Guowang Prip-Buus, Carina Savarin, Philippe Metabolites Article Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disorder that is implicated in dysregulations in multiple biological pathways, orchestrated by interactions between genetic predisposition, metabolic syndromes and environmental factors. The limited knowledge of its pathogenesis is one of the bottlenecks in the development of prognostic and therapeutic options for MAFLD. Moreover, the extent to which metabolic pathways are altered due to ongoing hepatic steatosis, inflammation and fibrosis and subsequent liver damage remains unclear. To uncover potential MAFLD pathogenesis in humans, we employed an untargeted nuclear magnetic resonance (NMR) spectroscopy- and high-resolution mass spectrometry (HRMS)-based multiplatform approach combined with a computational multiblock omics framework to characterize the plasma metabolomes and lipidomes of obese patients without (n = 19) or with liver biopsy confirmed MAFLD (n = 63). Metabolite features associated with MAFLD were identified using a metabolome-wide association study pipeline that tested for the relationships between feature responses and MAFLD. A metabolic pathway enrichment analysis revealed 16 pathways associated with MAFLD and highlighted pathway changes, including amino acid metabolism, bile acid metabolism, carnitine shuttle, fatty acid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism and steroid metabolism. These results suggested that there were alterations in energy metabolism, specifically amino acid and lipid metabolism, and pointed to the pathways being implicated in alerted liver function, mitochondrial dysfunctions and immune system disorders, which have previously been linked to MAFLD in human and animal studies. Together, this study revealed specific metabolic alterations associated with MAFLD and supported the idea that MAFLD is fundamentally a metabolism-related disorder, thereby providing new perspectives for diagnostic and therapeutic strategies. MDPI 2022-11-08 /pmc/articles/PMC9693407/ /pubmed/36355164 http://dx.doi.org/10.3390/metabo12111081 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lin, Xiangping Liu, Xinyu Triba, Mohamed N. Bouchemal, Nadia Liu, Zhicheng Walker, Douglas I. Palama, Tony Le Moyec, Laurence Ziol, Marianne Helmy, Nada Vons, Corinne Xu, Guowang Prip-Buus, Carina Savarin, Philippe Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach |
title | Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach |
title_full | Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach |
title_fullStr | Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach |
title_full_unstemmed | Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach |
title_short | Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach |
title_sort | plasma metabolomic and lipidomic profiling of metabolic dysfunction-associated fatty liver disease in humans using an untargeted multiplatform approach |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693407/ https://www.ncbi.nlm.nih.gov/pubmed/36355164 http://dx.doi.org/10.3390/metabo12111081 |
work_keys_str_mv | AT linxiangping plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT liuxinyu plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT tribamohamedn plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT bouchemalnadia plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT liuzhicheng plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT walkerdouglasi plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT palamatony plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT lemoyeclaurence plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT ziolmarianne plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT helmynada plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT vonscorinne plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT xuguowang plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT pripbuuscarina plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach AT savarinphilippe plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach |